The global hypoparathyroidism treatment market is on the cusp of notable growth, according to a comprehensive analysis ...

Adults with hypoparathyroidism treated with TransCon PTH in the phase 3 PaTHway open-label trial extension demonstrated ...

The global bionic eye market is set to experience substantial growth, advancing at a compound annual growth rate (CAGR) of 12 ...

TTR stabilizer in clinical development, lived longer and better as shown in the ATTRibute-CM study. This is the only Phase 3 ...

Total gross proceeds from upsized initial public offering and Series C financing were approximately $251.2 million Last ...

Michele Rayes used to take 64 pills a day to manage her hypoparathyroidism, a rare endocrine disorder that impairs calcium levels, dampens daily quality of life and can sometimes lead ...

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Entera Bio (ENTX – Research Report) today and set a price target of ...

And, when present on all 20 nails, it’s “usually the result of systemic disease such as mumps, pneumonia, coronary thrombosis ...

Q3 2024 Earnings Call Transcript November 6, 2024 Royalty Pharma plc misses on earnings expectations. Reported EPS is $0.918 ...

Thyroid diseases affect up to 5% of all pregnancies. Adverse pregnancy and neonatal outcomes are increased by maternal thyroid disease and adequate treatment is thought to reduce these risks ...